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Edited by Varda RotterAbstract Although signal transducer and activator of transcrip-
tion 1 (STAT1) mediated regulation of p53 transcription and
apoptosis has been previously reported, modulation of other
members of the p53 family of transcription factors remains
poorly understood. In this study, we found that STAT1 and
TA-p73 can interact directly and that p73-mediated Bax pro-
moter activity was observed to be reduced by STAT1 expression
in a p53-independent manner for which STAT1 Tyrosine-701
and Serine-727 are key residues. This study presents the ﬁrst
report physically linking STAT1 and TA-p73 signalling and
highlights the modulation of the Bax promoter in the context
of IFN-c stimulation.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Signal transducer and activator of transcription 1;
Interferon-gamma; TA-p73; p53; Bax1. Introduction
Originally identiﬁed as key intermediates in interferon (IFN)
signalling [1], the STAT (signal transducer and activators of
transcription) proteins have gained considerable attention re-
cently as regulators of cell growth and apoptosis [2,3]. In order
to activate STAT1 fully, phosphorylation of Tyrosine-701 by
Janus kinase (JAK) and dimerisation has been shown to be a
pre-requisite in addition to the phosphorylation of STAT1
on Ser-727 in a mitogen-activated protein kinase-dependent
manner [4–6]. As a key transcription factor activated during
stress-response signaling, STAT1 has also been demonstrated
to interact with p53 and potentiate apoptotic signaling [7]. Tar-
get genes that have been demonstrated to be transcriptionally
enhanced by the combination of STAT1 and p53 activation in-Abbreviations: STAT1, signal transducer and activator of transcription
1; MEF, murine embryonic ﬁbroblast; IFN-c, interferon-gamma;
GST, glutathione S-transferase; PBS, phosphate-buﬀered saline; aa,
amino acids
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doi:10.1016/j.febslet.2007.02.049clude p21waf [8,9], Bcl-2 associated protein X (Bax), Noxa and
Fas [7].
As member of the p53 transcription factor family, TA-p73 is
a modular protein whose activity is under stringent control, in
a transcriptional, translational and post-translational manner
[10]. The TA-p73 protein is expressed as 7 functionally distinct
C-terminal spliced variants arising from the alternative splicing
of the TA-p73 mRNA [11–13]. Trans-activating TA-p73 can
bind p53-responsive elements and activate p53 target genes in-
volved in cell cycle arrest and apoptosis [14].
The Bcl-2 family of anti-apoptotic and pro-apoptotic pro-
teins, all of which possess one or more Bcl-2 homology
domains, are regulated by post-translational modiﬁcation,
sub-cellular localization and dimerisation [15]. As a pro-apop-
totic member of this family, Bax is transcriptionally up-regu-
lated by TA-p73 (as is PUMA). The time kinetics of this
event during the induction of cell death is consistent with
PUMA mediated Bax translocation, rather than expressed-
TA-p73 directed Bax translocation [16], highlighting a pro-
apoptotic role for TA-p73.
Considering that the Bax promoter can also be positively
regulated by p53 [7,17], the underlying mechanisms that allow
the selective TA-p73 mediated Bax regulation in the absence of
p53 mediated Bax expression, remain uncharacterized. In this
context, key regulators and up-stream signaling intermediates
of TA-p73 and p53 have received considerable attention. As
we will show in this study, one such protein that is common
to the regulation of p73 (as well as p53) mediated gene regula-
tion is STAT1.
We show that STAT1 can physically associate with TA-p73
in vitro and in vivo, that TA-p73-directed Bax promoter activ-
ity and protein expression is signiﬁcantly reduced by STAT1
expression in mouse embryonic ﬁbroblast (MEF) cells in the
presence and absence of IFN-c stimulation and that this can
occur in a p53-independent manner.2. Materials and methods
2.1. Materials
Mouse and rat IFN-c were purchased from Sigma (UK). Rabbit
anti-STAT1 (sc-346), mouse anti-phospho 701 STAT1 (for use in co-
immunoprecipitations, Sc-8394), rabbit anti-Bax (sc-526), rabbit
anti-HA probe antibody (Y-11) and anti-b-actin were purchased from
Santa Cruz Biotechnology. Mouse anti-phospho-701 STAT1 (Zymed)
was used for Western blotting alone. Transfections were performed
using Fugene 6 (Roche) and used as recommended. The humanblished by Elsevier B.V. All rights reserved.
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(MRC Toxicology Unit, University of Leicester). Anti-Myc antibody
(Invitrogen), anti-HA antibody (clone 3F10, Roche), GAP-DH
(MAB 374, Chemicon) and mouse anti-STAT1 (SM2 mouse monoclo-
nal, Abcam) were also used in this study. Normal IgG antibodies and
Protein A/G-PLUS sepharose were purchased from Santa Cruz Bio-
technology.
2.2. Plasmids
STAT1-pGEX5X-2 was a gift from Behrmann [18]. Mammalian
Expression plasmids for HA-tagged human TA-p73 derived proteins
and bacterial expression plasmids for human TA-p73 derived glutathi-
one S-transferase (GST)-fusion proteins were gifts from G. Melino
(University Of Leicester) and have been described previously [12,19].
Human STAT1-a/MYC-pCDNA6A, STAT1-b/pRc/CMV, STA-
T1Y701F/pRc/CMV, STAT1S727A//pRc/CMV and mouse STAT3/
pCDNA3 expression plasmids were a generous gift from J. Darnell
(Rockefeller University, New York, USA) and have been described
previously [20]. The mammalian expression plasmid for HA-tagged hu-
man p53 expression plasmid (p53-HA) was a gift from G. Melino (Uni-
versity of Leicester).
2.3. Cell lines and reagents
COS-7 cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) as described previously [21]. STAT1 deﬁcient MEF cells
(STAT1/ MEF) and their wild-type counterparts were maintained
in supplemented DMEM (as above) containing 10% v/v FBS and,
non-essential amino acids and were a gift from David E. Levy [22].
Mice deﬁcient for STAT1 and p53 were generated by crossing
STAT1/129S6/SvEv [23] deﬁcient mice (purchased from Taconic, Den-
mark) with p53/C57BL/6J [24] deﬁcient mice (Taconic) giving rise to
double heterozygous mice, which were cross-bred with each other giv-
ing STAT1/p53/ deﬁcient embryos. Embryos were isolated at 13.5
days PC and MEF cells harvested following trypsin digestion and cul-
tured in DMEM containing 10% FBS with the above supplements and
genotyped for being STAT1/p53/ ‘double-knockout’ by PCR using
primers speciﬁc for STAT1 and p53 and by Western blotting.
STAT1/p53/ MEF cells were pooled and transfected with DNA
using Fugene 6 reagent after 3 passages.
2.4. Expression and puriﬁcation of GST fusion proteins
GST expression plasmids were used to transform competent BL-21
LysS (Promega) cells, which were then grown to log-phase at 37 C, in-
duced with 1 mM IPTG for 3 h at 30 C and GST fusion proteins iso-
lated by immobilization on glutathione Sepharose (Amersham
Biosciences) as outlined [21].
2.5. GST co-precipitation and co-immunoprecipitation assays
Transfected cells were lysed in 1% v/v Igepal-630, 50 mM Tris pH
8.0, 150 mM NaCl, 10% v/v glycerol, 5 mM EDTA, 1 mM PMSF,
20 lg/ml leupeptin, 10 lg/ml aprotinin, 1 mM NaF, 1 mM Na3VO4
(1%NP-40LB) and the cleared lysates were incubated with approxi-
mately 5 lg GST-Sepharose, GST-STAT1 or -p73 derivative-
Sepharose, incubated overnight at 4 C, washed 6 times in 0.1% v/v
Igepal-630, 50 mM Tris pH 8.0, 150 mM NaCl, 10% v/v glycerol, 5
mM EDTA, 1 mM PMSF, 20 lg/ml leupeptin, 10 lg/ml aprotinin, 1
mM NaF, 1 mM Na3VO4 (0.1%NP-40LB) and analysed by Western
blotting as described [21]. Identical lysis conditions were used for
co-immunoprecipitation of proteins and have been described [25].
2.6. Confocal microscopy
STAT1/ MEF cells were seeded on glass coverslips at a density
of 103 cells per 13 mm coverslip and transfected the following day
using Fugene 6 and incubated for another 24 h. Cells were ﬁxed in
Paraformaldehyde (PFA), permeablised in PFA, 0.1% v/v Triton X-
100 and stained using antigen speciﬁc antibodies as outlined [25].
Alexa-Fluor 488 donkey anti-mouse IgG, Texas Red goat anti-rat
conjugates were used as secondary antibodies (10 lg/ml) and were
purchased from Molecular Probes (Invitrogen). Coverslips were
mounted in Vecta Shield mounting mix containing DAPI (Vecta Lab-
oratories, UK), visualized at room temperature using a Leica TCS
SP2 Laser Scanning Confocal Microscope and with 63· objectives
and analysed using LCS Lite (Leica) and Adobe Photoshop 6.0
software.2.7. Luciferase reporter assays
MEF cells were seeded at 4 · 105 cells per well for 6 h, transfected (in
duplicate) using DNA/Fugene 6 complexes and the incubation contin-
ued for 48 h at 37 C.Human Bax-luciferase reporter plasmid was a
gift from G. Melino (University of Leicester). For standardization of
transfection eﬃciencies, 50 ng of b-galactosidase/pRSV plasmid was
also added to the transfection mix. Following incubation and stimula-
tion the cells were washed in 1· PBS (lacking Ca2+ and Mg2+ ions) and
lysed in reporter assay lysis buﬀer. 5 ll of cleared lysate was assayed
for luciferase activity using the Luciferase Assay System (Promega)
and for b-galactosidase activity using the Beta-Glo system (Promega).
Luciferase data were recorded (in duplicate) using a TD-20e lumino-
meter (Turner Designs, USA) and the data presented are from one
set of experiments for which consistency was observed for at least 3
times.
2.8. Isolation of rat cardiomyocyte cells
Two days old Sprague–Dawley neonatal rats were used as heart tis-
sue donors from which cardiomyocyte cells were isolated and main-
tained as outlined previously [26].
2.9. Statistical analysis
Luciferase data were analysed using Microsoft Excel (Microsoft,
USA) to determine the standard error around the mean, before the re-
sults were translated to fold activation of relative light units over basal
control experiments.3. Results
3.1. STAT1 interacts with TA-p73 in vitro
To investigate whether STAT1 interacts with TA-p73 we
transfected STAT1 deﬁcient Mouse Embryonic Fibroblast
cells (STAT1/ MEF) cells with STAT1-a (pSTAT1-a/
MYC) or STAT3 (STAT3/pCDNA3.1+) encoding plasmids
and conducted co-precipitation experiments with GST-TA-
p73 Sepharose. Upon the analysis of GST-TA-p73 Sepharose
complexes by Western blotting using an anti-STAT1 or
-STAT3 antibody (Fig. 1a), STAT1 alone was observed to di-
rectly interact with GST-TA-p73.
To determine which region of the TA-p73 protein sequence
[27] is responsible for interacting with STAT1-a, we next per-
formed co-precipitation experiments with GST-fused deletion
derivatives of TA-p73 (Fig. 1b). PCDNA3.1+ transfected cells
and STAT1-a/MYC expressing cells were used as negative and
positive controls, respectively. As shown in Fig. 1c, GST-TA-
p73 could interact with STAT1-a/MYC within the regions that
mapped to the amino- and carboxyl-terminals (albeit with dif-
fering aﬃnities) with TA-p73 DNA binding domain (DBD)
interacting the strongest. GST-TA-p73 amino acids 313–486
(OD domain) did not exhibit any binding to STAT1-a/MYC.
As a positive control for this experiment, we could demon-
strate the interaction of expressed STAT1-a with GST-
STAT1-a, presumably in the absence of STAT1Y701
phosphorylation as shown previously [28,29]. Additionally,
TA-p73 binding sites for GST-STAT1 were also determined
using co-precipitation. Cells transfected with empty expression
plasmid (pCDNA.1+) or p53-HA expression plasmid were
used as negative and positive controls, respectively. HA-tagged
TA-p73 derivatives and the DeltaN-p73 isoform lacking the N-
terminal transactivation domain [35,37] were expressed in
COS-7 cells and cell supernatants incubated with GST-STAT1
Sepharose. Upon analysis of the co-precipitation complexes,
all TA-p73 derived protein constructs were found to interact
with GST-STAT1 except the construct that encoded p73 ami-
no acids 313–486 (OD domain, Fig. 1d).
Fig. 1. STAT1 directly interacts with TA-p73. (a) STAT1/MEF cells were transfected with 1 lg of plasmid encoding STAT1-a/MYC or STAT3.
Forty-eight hours after transfection cells were lysed, cleared and the whole cell lysates (WCL) incubated with GST- or GST-TA-p73 Sepharose
overnight. Co-precipitation mixtures were washed, resolved by SDS–PAGE and analysed by Western blotting (WB) using an anti-STAT1 antibody
(left panel) and an anti-STAT3 antibody (right panel). (b) Diagramatic representation of the TA-p73-GST fusion proteins used to map the STAT1
speciﬁc binding site. The Amino-Terminal Domain (NTD) harboring the Transactivation Domain (TA, aa 1-54), DNA Binding Domain (DBD, aa
131-310), Oligomerisation Domain (OD, aa 345-380) and the Carboxyl-Terminal Domain (CTD) harboring the Sterile Alpha Motif domain (SAM,
aa 484–549) are shown. (c) STAT1/MEF cells were transfected with pCDNA3.1+ (1 lg) or STAT1-a/MYC and 48 h after transfection, cells were
lysed and cleared whole cell lysates (WCL) were incubated with 5 lg of GST-Sepharose, GST-TA-p73 derived Sepharose conjugates or GST-
STAT1a Sepharose conjugates (as revealed by Coomassie staining). Eighteen hours later, co-precipitation mixtures were washed and resolved using
SDS–PAGE and analysed by Western blotting (WB) with an anti-MYC antibody. (d) STAT1/ MEF cells were transfected with 1 lg of
pCDNA3.1+, p53-HA and the TA-p73-HA derived expression plasmids. Forty-eight hours later, cells were washed, lysed and cleared whole cell
lysates (WCL) were incubated overnight with approximately 5 lg GST- or GST-STAT1a Sepharose. Co-precipitation mixtures were harvested,
washed, resolved and analysed by Western blotting (WB) with an anti-HA antibody (top and lower panels). Equal volumes of WCLs were analysed
for positive expression of the p73-derived proteins (middle panel) and quantities of GST- or GST-STAT1 Sepharose used in the binding assays were
revealed by Coomassie staining.
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interact with TA-p73-HA and that the regions within TA-
p73 that are responsible for this span amino acids 1–312 and
487–637. Similarly, the catalytic subunit of PKA has also been
shown to interact with TA-p73 amino acids 63–130 (TA do-
main) and 469–637 (SAM domain) but not amino acids 311–
483 [30], highlighting that the TA-p73 binding sites for STAT1
are not exclusive and that these sites may also mediate interac-
tions with other signaling proteins.
3.2. STAT1 interacts with TA-p73 in intact cells
As STAT1Y701 and STAT1S727 have been demonstrated
to be key residues in mediating the dimerisation, transloca-
tion of STAT1 and the optimization of STAT1-mediated
transcriptional activity, we next addressed the dispensability
of these residues in mediating the interaction between
STAT1 and TA-p73 in mammalian cells using co-immuno-
precipitation experiments. Therefore, STAT1/ MEF cellswere co-transfected with pCDNA3.1+, STAT1-a, STAT1-b
[31], STAT1Y701F, STAT1S727A and pTA-p73-HA, lysed
and TA-p73 immunoprecipitated using an anti-HA antibody.
Upon analysis of co-immunoprecipitation complexes, TAp73-
HA was found to immunoprecipitate equivalently in all
transfections, all STAT1 derivatives were found to positively
interact with TA-p73, with STAT1S727A and STAT1-b inter-
acting weakly (Fig. 2) as reported previously between
STAT1S727A and the CBP co-activator protein [6,32]. As a
positive control, STAT1-a was found to strongly interact
with p53-HA [7]. By comparison, TAp73-HA binding to
STAT1-a was observed to be relatively low, due possibly to
it interacting relatively weakly to STAT1 since the expressed
levels of p53-HA and TA-p73-HA were observed to be quite
equivalent. Moreover, STAT1 expression levels were ob-
served to be fairly consistent, with the exception of STA-
T1Y701F, which either expressed at relatively higher levels
or possesses greater protein stability.
Fig. 2. STAT1 interacts with TA-p73-HA in intact cells. STAT1/
MEF cells were transfected with 0.5 lg of TA-p73-HA and 0.5 lg
pCDNA3.1+, p53-HA or the indicated STAT1 derived expression
plasmids. Forty-eight hours after transfection, cells were washed, lysed
and TA-p73 immunoprecipitated (IP) using an anti-HA antibody
(3 lg) or Normal IgG (NIgG) antibody. Immune complexes were
washed and resolved using SDS–PAGE and analysed by Western
blotting (WB) with an anti-STAT1 antibody. Equal volumes of Whole
cell lysates (WCL) were also analysed by Western blotting to detect
expression levels of p5 3-HA, STAT1 constructs and pTA-73-HA.
Fig. 3. STAT1 and TA-p73-HA localisation in STAT1/ MEF cells.
STAT/MEF cells grown on cover slips were transfected with 0.5 lg
TA-p73-HA (or p53-HA) and 0.5 lg STAT1 derived expression
plasmids (in duplicate). Forty-eight hours after transfection, cells were
washed, ﬁxed using paraformaldehyde, permeablised and stained using
STAT1-a (anti-MYC, green channel) or anti-STAT1a/b speciﬁc
antibody (green channel) and anti-HA antibodies (red channel). Cover
slips were mounted and visualized using laser scanning confocal
microscopy. Regions of co-localization are indicated by white arrows.
Cells expressing STAT1-a/MYC (green channel) and TA-p73-HA (red
channel) were also stained with the corresponding non-immune IgG
antibodies (NIgG) as negative controls.
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STAT11 MEF cells
Considering that STAT1 derivatives display diﬀerential bind-
ing by pTA73 (Fig. 2), in beginning to determine whether this
is due to diﬀering subcellular compartmentalization of these
two proteins, we utilized laser scanning confocal microscopy to
image expressed STAT1 derivatives and pTA73. STAT1/
MEF cells were transfected using plasmids that encode
STAT1-a/MYC, STAT1Y701F, STAT1-b, STAT1S727A with
HA-tagged TA-p73 (pTA-p73-HA). STAT1-a/MYC and p53-
HA were utilized as a positive control and observed to be
respectively present in the cytoplasm and nucleus as seen pre-
viously [7]. In Fig. 3, STAT1-a, STAT1-b [31] and STAT1-
S727A were seen to be present in distinct compartments
within the cytoplasm (presumably as latent STAT1) which is
in good agreement with previously published observations
[29,33]. Additionally, all STAT1 derivatives were observed to
show some co-localisation with TA-p73 to varying degrees
with TA-p73-HA within the cytoplasm [34] or nucleus [35].
Collectively, these data suggest that expressed STAT1-a/
MYC and TA-p73-HA can co-localize within the cytoplasmand nucleus of STAT1/ MEF cells conﬁrming the speciﬁc
interaction of TA-p73 with STAT1 (Fig. 2).
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To test the above ﬁndings in a cell system that does not uti-
lize the artiﬁcial expression of TA-p73 or STAT1, we next con-
ducted co-precipitation experiments between STAT1-a and
GST-TA-p73 using cell supernatants derived from primary
neonatal cardiomyocyte cells (CM), as seen between STAT1
and p53 [7]. Primary CM cells were stimulated with IFN-c,
lysed and cleared supernatants incubated with GST-alone or
GST-TA-p73 protein immobilized on glutathione Sepharose.
As shown in Fig. 4, endogenous phospho-STAT1a and b were
found to positively interact with GST-TA-p73 Sepharose in an
IFN-c stimulatory manner as early as 10 min after stimulation
which was maximal after 45–60 min.
3.5. TA-p73 expression activates the Bax promoter
As we observed STAT1+/+ cells to express relatively low
amounts of TA-p73 (S.M. Soond, unpublished), we ﬁrst
sought to establish what quantities of expressed pTA73-HA
could activate the Bax promoter in the presence and absence
of IFN-c stimulation. Therefore, STAT1+/+ MEF cells were
transfected with an increasing dose of TA-p73-HA expression
plasmid, followed by IFN-c stimulation before cells were lysed
and ﬁxed volumes of supernatant evaluated for luciferase
activity. As shown in Fig. 5a, we observed a TA-p73 dose
dependent increase in Bax promoter activity (over
pCDNA3.1+ transfected cells), which peaked at 1 lg of trans-
fected TA-p73 DNA. Moreover, upon stimulation of cells with
IFN-c, the relative amounts of luciferase activity was observed
to be reduced by approximately 30%.
3.6. STAT1 negatively regulates TA-p73-mediated Bax
promoter activity
Next we addressed the regulatory eﬀects of STAT1 expres-
sion on TA-p73 mediated Bax promoter activation. Therefore,Fig. 4. Activated STAT1 interacts with TA-p73 in neonatal primary
cardiomyocyte cells. Primary CM (106) were stimulated using 25 ng/ml
rat IFN-c for the indicated times. At each time point cells were
washed, lysed and the whole cell lysates (WCL) incubated with
approximately 5 lg GST- or GST-TA-p73 Sepharose overnight. Co-
precipitates were washed and resolved using SDS–PAGE followed by
Western blotting (WB) with an anti-phospho-701 STAT1 (p-STAT1)
antibody. Quantities of incubated GST- or GST-TA-p73 Sepharose
were revealed by Coomassie staining.TA-p73-HA plasmid with increasing amounts of pSTAT1-a/
MYC were used to transfect STAT1/ MEF, cells stimulated
with IFN-c and cleared lysates assayed for luciferase reporter
activity. Fig. 5b shows that with increasing amounts of
STAT1-a expression, decreasing levels of Bax promoter
activity were observed. Additionally, when 1 lg of STAT1-a
encoding plasmid was used in the transfection mix followed
by IFN-c stimulation, we observed 50% reduction in Bax
promoter activity. In this manner, STAT1-a expression in
the absence of TA-p73-HA expression, followed by IFN-c
stimulation had no signiﬁcant change on Bax promoter activ-
ity in comparison to pCDNA3.1+ transfected cells, eliminating
the possibility of STAT1-a modulating the Bax promoter di-
rectly in our system (S.M. Soond, unpublished). Collectively,
these data suggest that STAT1-a downregulates TA-p73 med-
iated Bax promoter activity and that this is further suppressed
in the presence of IFN-c stimulation in our reconstituted
STAT1/MEF cell based system, which is consistent with
the observations see in STAT1+/+ cells expressing TA-
p73-HA (Fig. 5a).
3.7. STAT1 Ser-727 is critical in regulating TA-p73 mediated
Bax expression
In view of maximum STAT activation requiring the phos-
phorylation of Tyr-701 by JAK kinase and the possible
MAPK phosphorylation of STAT1 Ser-727 [4,5], we next
sought to address the dispensability of these residues in
STAT-a mediated abrogation of TA-p73 induced Bax pro-
moter activation. Therefore, we transfected STAT1/ MEF
cells with pCDNA3.1+, pTA-p73-HA and STAT1-a/MYC,
pSTAT1-b, pSTAT1Y701F or pSTAT1S727A expression
plasmids , stimulated them for 24 h using IFN-c before cell
lysates were prepared and assayed for Bax promoter activity.
As seen from Fig. 5c, plasmids encoding STAT1-a, STAT1-b
and STAT1Y701F resulted in reduced Bax promoter activa-
tion in the presence and absence of IFN-c stimulation. How-
ever, STAT1S727A was observed to show elevated levels of
Bax promoter activation in the absence and presence of
IFN-c stimulation, in comparison to STAT1-a. Collectively,
these data suggest that under IFN-c stimulatory and non-
stimulatory conditions, abrogation of TA-p73 mediated Bax
promoter activation is heavily dependent upon modiﬁcation
of STAT1 Ser-727 in STAT1/ MEF cells. Considering
that STAT1-b and STAT1S727A lack the Ser-727 phosphor-
ylation site and yet yield obvious diﬀerences in p73 mediated
Bax promoter regulation, we next sought to address whether
this may be due to changes in STAT1 or TA-p73 sub-cellu-
lar location upon IFN-c stimulation of cells. Therefore,
STAT1/ cells transfected with expression plasmids encoding
STAT1-a/MYC, STAT1-b and STAT1S727A were stimulated
with mouse IFN-c and the cells ﬁxed, permeablised and
stained for STAT1 and TA-p73-HA expression. Cells were
imaged using laser scanning confocal microscopy (Fig. 6)
and STAT1 found to localise to the nucleus (as did STA-
T1727A), whereas STAT1-b was seen to localise to a perinu-
clear compartment mainly composed of vessicular structures,
implying that TA-p73 may (at least in part) be spatially reg-
ulated by STAT1-a and STAT1-b. Moreover, STAT1Ser-
727 and the surrounding protein sequence may be of relative
importance in accounting for the relative diﬀerences seen in
IFN-c mediated TA-p73 Bax promoter regulation upon
STAT1 expression.
Fig. 5. Bax promoter activation is abrogated in STAT1+/+MEF cells expressing STAT1-a for which STAT1 Ser-727 is required. (a) STAT1+/+ cells
were transfected with pCDNA3.1+ or with the stated amounts of TA-p73-HA expression plasmid along with 250 ng Bax-luciferase and 50 ng b-
galactosidase/pRSV. Transfecting DNA was kept constant using pCDNA3.1+ plasmid. Forty-eight hours after transfection, cells were either left un-
stimulated (white bars) or stimulated with mouse IFN-c (50 ng/ml, black bars) for 24 h. Cells were washed and lysed before ﬁxed volumes of lyate
were analysed for relative luciferase activity. Luciferase activity was standardized for transfection eﬃciency, and is expressed as fold activation over
basal. Whole cell lysates were also analysed for TA-p73 (TA-p73-HA), activated phospho-Y701STAT1 (pSTAT1), and GAP DH expression using
Western blotting. (b) STAT1/ cells were transfected with 1 lg of pCDNA3.1+ or TA-p73-HA expression plasmid along with the stated amounts of
STAT1-a/MYC expression plasmid and 250 ng Bax-luciferase and 50 ng b-galactosidase/pRSV. Transfection DNA was kept constant using
pCDNA3.1+ plasmid. Forty-eight hours after transfection, cells were either left un-stimulated (white bars) or stimulated with mouse IFN-c (50 ng/
ml, black bars) for 24 h. Cells were washed and lysed before ﬁxed volumes of lysate were analysed for relative luciferase activity. Luciferase activity
was standardized for transfection eﬃciency, and is expressed as fold activation over basal. Whole cell lysates were also analysed for TA-p73 (TA-p73-
HA), STAT1-a, activated phospho-Y701STAT1 (pSTAT1), and GAP DH expression using Western blotting. (c) STAT1/ cells were transfected
with 1 lg of pCDNA3.1+ or TA-p73-HA expression plasmid along with 2 lg STAT1 expression plasmids and 250 ng Bax-luciferase and 50 ng b-
galactosidase/pRSV. Transfection DNA was kept constant using pCDNA3.1+ plasmid. Forty-eight hours after transfection, cells were either left un-
stimulated (white bars) or stimulated with mouse IFN-c (50 ng/ml, black bars) for 24 h. Cells were washed and lysed before ﬁxed volumes of lyate
were analysed for relative luciferase activity. Luciferase activity was standardized for transfection eﬃciency, and is expressed as fold activation over
basal. Whole cell lysates were also analysed for TA-p73 (TA-p73-HA), STAT1-a (STAT1), activated phospho-Y701STAT1 (pSTAT1), and GAP
DH expression using Western blotting.
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To extend our observations from above, we next analysed the
expression of the Bax protein under IFN-c stimulatory condi-
tions in STAT1+/+ and STAT1/MEF cells. Therefore, equal
quantities of MEF cells were seeded and left un-stimulated or
stimulated for 1–24 h using IFN-c and analysed by Western
blotting using a Bax speciﬁc antibody. From the data presented
(Fig. 7), STAT1+/+ MEF cells expressed less Bax protein in
comparison to STAT1/ cells, which was observed to signiﬁ-
cantly decrease in STAT1+/+ cells after 24 h of IFN-c stimula-tion in comparison to STAT1/ cells, in cell lysates equivalent
in b-actin expression. Collectively, these observations suggest
that IFN-c stimulation of MEF cells up to 24 h, results in
downregulation of Bax protein expression and that this occurs
in a STAT1 expression-dependent manner.
3.9. STAT1 downregulates TA-p73 mediated Bax promoter
activation independently of p53
In light of the observation that p53 may positively regulate
the expression of the TA-p73 inhibitor DeltaN.p73 [36], we
Fig. 6. Sucellular location of STAT1 and TA-p73 in IFN-c stimulated
cells. STAT1/ MEF cells (seeded on coverslips) were transfected
with 0.5 lg of TA-p73-HA along with 0.5 lg of the indicated STAT1
expression plasmids. Forty-eight hours after transfection, cells were
stimulated for 24 h with mouse IFN-c (50 ng/ml), ﬁxed, permeablised,
stained for STAT1 (green channel), TA-p73-HA (red channel) and the
nucleus (blue channel, using DAPI) and imaged using laser scanning
confocal microscopy. Regions of co-localisation are indicated with
arrows.
Fig. 7. STAT1 expression downregulates Bax protein expression fol-
lowing IFN-c stimulation. STAT1/ and STAT1+/+ MEF cells
(0.5 · 105) were left un-stimulated or stimulated for the indicated
hours (hrs) using 50 ng/ml mouse IFN-c. Cells were washed, lysed and
proteins resolved using SDS–PAGE and analysed by Western blotting
with anti-Bax (-Bax), anti-phosphoY701-STAT1 (-pSTAT) and anti-b
actin (-Actin) antibodies.
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downregulation of Bax promoter activity by TA-p73 occurs
in a p53 dependent manner. To this end, we generated
STAT1/p53/ ‘double-knockout’ MEF cells, which we co-
transfected with the Bax-luciferase reporter construct, TA-
p73-HA expression plasmid with an increasing dose of
STAT1-a expression. Forty-eight hours after transfection, cells
were stimulated with IFN-c for 24 h after which, cell lysates
were assayed for relative luciferase activity. As shown in
Fig. 8a, STAT1 expression in these cells resulted in a dose-
dependent decrease in Bax reporter activity, which could be
inducibly downregulated in the presence of IFN-c stimulation.
Additionally, we attempted to detect endogenous Bax
protein expression by comparing p53/ cells and STAT1/
p53/ cells during a time course of IFN-c stimulation (as in
Fig. 7). However, our attempts to detect the Bax protein in this
analysis were unsuccessful (S. M. Soond, unpublished) and we
propose that this could be due to Bax protein expression hav-
ing an intrinsic requirement for p53 expression, as reported
previously [37,38].3.10. STAT1 Tyr-701 and Ser-727 residues are both important
in TA-p73 mediated Bax promoter downregulation in the
absence of p53 expression
Next asked how dispensable residues STAT1Y701 or
STAT1S727 are in regulating the transcriptional activity of
TA-p73 independently of p53. Therefore, STAT1/p53/
MEF cells were transfected with pCDNA3.1+ alone, pTA-
p73-HA and pCDNA3.1+, pSTAT1-a/MYC, pSTAT1Y701A
or pSTAT1S727A expression plasmid. Forty-eight hours later
cells were stimulated with IFN-c for 24 h before cell lysates
were prepared and assayed for relative luciferase activity. As
shown in Fig. 8b, STAT1-a expression followed by IFN-c
stimulation resulted in downregulation of TA-p73 mediated
Bax promoter activity which was signiﬁcantly reduced upon
expression of STAT1Y701F and STAT1S727A with or with-
out IFN-c stimulation. These data suggest that for the
STAT1-a dependent downregulation of TA-p73 mediated
Bax promoter activity, STAT1-a requires residues Tyr-701
and Ser-727. This is in contrast to when STAT1/p53+ MEF
cells are used in such an experiment (Fig. 5c), where STAT1
Ser-727 was seen to be important for STAT1 mediated Bax
promoter abrogation.4. Discussion
Based on the knowledge that TA-p73 and p53 can bind iden-
tical transcriptional regulatory sequences, it is no surprise that
both of these transcription factors mediate the regulation of an
overlapping repertoire of genes, such as p21, PUMA, p53R2
and Bax. In view of this, one of the key challenges in this ﬁeld
is how these transcription factors may be biochemically regu-
lated, giving rise to diﬀerential and speciﬁc down-stream gene
Fig. 8. STAT1 expression in STAT1/p53/ MEF cells abrogates TA-
p73 mediated Bax promoter activity for which STAT1 Tyr-701 and
STAT1 Ser-727 are required. (a) STAT1/p53/ MEF cells were
transfected with 1 lg of pCDNA3.1+ or TA-p73-HA expression
plasmid with the shown quantities of STAT1-a expression plasmids,
250 ng Bax-luciferase and 50 ng b-galactosidase/pRSV plasmids. DNA
amounts were kept constant using pCDNA3.1+ plasmid. Forty-eight
hours after transfection, cells were either left un-stimulated (white
bars) or stimulated with mouse IFN-c (50 ng/ml, black bars) for 24 h.
Cells were washed and lysed before ﬁxed volumes of lysate were
analysed for relative luciferase activity. Luciferase activity was
standardized for transfection eﬃciency, and is expressed as fold
activation over basal. Whole cell lysates were also analysed for TA-p73
(TA-p73-HA), STAT1-a (STAT1), activated phospho-Y701STAT1
(pSTAT1), and GAP DH expression using Western blotting. (b)
STAT1/p53/ MEF cells were transfected with 1 lg of pCDNA3.1+
or TA-p73-HA expression plasmid along with 0.5 lg STAT1 expres-
sion plasmids, 250 ng Bax-luciferase and 50 ng b-galactosidase/pRSV.
DNA amounts were kept constant using pCDNA3.1+ plasmid. Forty-
eight hours after transfection, cells were either left un-stimulated (white
bars) or stimulated with mouse IFN-c (50 ng/ml, black bars) for 24 h.
Cells were washed and lysed before ﬁxed volumes of lysate were
analysed for relative luciferase activity. Luciferase activity was
standardized for transfection eﬃciency, and is expressed as fold
activation over basal. Whole cell lysates were also analysed for TA-
p73-HA (TAp73-HA), STAT1-a (STAT1), activated phospho-
Y701STAT1 (pSTAT1), and GAP DH expression using Western
blotting.
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tory have addressed this in light of p53 gene regulation by acti-
vated STAT1-a in the presence of DNA damaging agents and
ischaemia-reperfusion injury [7,20], the regulatory role played
by STAT1 on TA-p73 directed Bax expression during IFN-c
signalling, remains poorly understood.
To date, the Bax promoter has been demonstrated to be reg-
ulated by a number of proteins which include p53 and TA-p73.Data published previously have demonstrated that the Bax
promoter can be activated upon TA-p73 overexpression
[30,39,40]. Moreover, overexpression of p73 has been reported
in various tumour types when compared with normal tissues
[41–45] and has been reported to confer resistance to p53-med-
iated apoptosis induced by certain chemotherapeutic agents
[46]. This is demonstrated in p73-deﬁcient neurons exhibiting
enhanced apoptosis in vivo [47]. Using an approach that uti-
lized TA-p73 expression, we demonstrated that STAT1 expres-
sion downregulated Bax promoter activity in an IFN-c
dependent manner and Ser-727 phosphorylation is critical
for this to occur in a p53-dependent manner within
STAT1p53+MEF cells. Although, maximum activation of
STAT1 is dependent upon the phosphorylation of Y701 by
JAK kinase [5], STAT1Ser-727 phosphorylation has been
shown to be critical for maximum STAT1 activation and
STAT1-mediated cell death [4,7,48]. However, STAT1-b [31]
which lacks the STAT1Ser-727 phosphorylation site and car-
boxyl-terminal amino acids (which are otherwise present in
STAT1-a) also produces diminished Bax promoter activity in
contrast to STAT1S727A (in STAT1/ MEF cells, Fig. 5c),
in addition to it being able to interact with TA-p73 (Figs. 4a
and 2) and co-localise with it (Fig. 6) suggesting that the
underlying mechanism is clearly very complex (which could
be STAT1-a or STAT1-b speciﬁc) and that TA-p73/STAT1
protein traﬃcking may be of importance in regulating TA-
p73 mediated Bax expression in a p53 dependent manner.
Moreover, in the absence of p53 expression, we observed that
STAT1 required residues Tyr-701 and Ser-727 to downregulate
TA-p73 mediated Bax promoter activation. We propose that
this may highlight a distinct mechanism (however complex)
by which TA-p73 (in comparison to p53) may regulate Bax
promoter regulation based upon the phosphorylation status
of STAT1 and the presence of p53.
In a manner similar to p53, TA-p73 is stabilized at the pro-
tein level in response to DNA damaging agents permitting it to
mediate its pro-apoptotic transcriptional activity [49]. Positive
stabilizers of TA-p73 protein and activity include MDM2 [50]
– as in the case of p53 [51–53], YAP [54], and phosphorylation
by PKC-d [55]. Conversely, TA-p73 activity can be negatively
regulated by cyclin G [56], SUMO-1 [57], PIAS-1 [19] calpain I
[58], UFD2a [39], PKA-Cb [30] and Itch [59]. Other identiﬁed
binding partners to TA-p73 include HMGB1 and HMGB2,
which stimulate or abrogate the binding of TA-p73 to p53
responsive elements (within the Bax promoter) in a cell speciﬁc
manner [40]. With these observations in mind, how STAT1-a
regulates the activity of endogenous TA-p73 induced Bax pro-
moter and protein expression, mechanistically, requires further
study. FromWestern blotting, analysis of the whole cell lysates
for TA-p73 expression (Fig. 5), we do not observe a decrease in
the stability of TA-p73 in response to STAT1 expression and
IFN-c stimulation that may explain the observed IFN-c med-
iated inducible reduction in Bax promoter activity. Although,
this may be a consequence of artiﬁcially expressing TA-p73,
the observation that Bax promoter activity is marginally in-
creased in response to IFN-c stimulation in pCDNA3.1+
transfected STAT1+/+ MEF cells (Fig. 5a) argues against this
possibility. Additionally, based upon the observation that
STAT1 can interact strongly with the DBD domain of TA-
p73 (Fig. 1b), this may suggest that STAT1 may interact with
TA-p73 thereby reducing the ability of TA-p73 to bind DNA
and activate transcription.
S.M. Soond et al. / FEBS Letters 581 (2007) 1217–1226 1225The consequential modulation of TA-p73 by activated
STAT1 may also be mediated indirectly through the induction
of Interferon-Regulatory Factor-1 [60] and remains to be ex-
plored further. However, evidence linking IFN-c stimulation
with the downregulation of the Bax gene has been reported
previously in MDA-MB213 breast carcinoma [61] and rat liver
cells [62], supporting our observations and highlighting an
important role for STAT1 as an upstream negative-regulator
of the Bax promoter via TA-p73.
In summary, our ﬁndings suggest that STAT1 can physically
associate with TAp73 and that in MEF cells can downregulate
TAp73 mediated Bax promoter activation and Bax protein
expression. Our observations also suggest that this decrease
in Bax promoter activity is induced upon IFN-c stimulation
of MEF cells and that STAT1Ser-727 modiﬁcation is required
for this. In consideration of previously published data, where
STAT1 has been shown to interact and potentiate the activity
of p53 in response to DNA damage and cellular stress [7], we
propose that STAT1-dependent reduction of TAp73 mediated
Bax gene regulation may present a potential mechanism that
allows selective regulation of the TAp73 and TAp53 family
of transcription factors for a common set of transcriptionally
regulated genes.
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